These findings have relevant implications on clinical practice, including the possibility of refining the individual prognostic prediction and improving the design of ALS clinical trials, in particular as regards as those targeted explicitly to ATXN2. This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.